Slides
Page 1
SCIENCE FOR PEOPLE ADVANCING IMPACT Biocon Limited Q1 FY27 Earnings Call 06 - Aug - 2026 Biocon
Page 2
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.
Page 3
Chairperson’s Opening Remarks
Page 4
Positioned for the Next Phase of Growth ▪ Integrated platform, global scale and resilient supply networks position Biocon for sustained growth ▪ North America: largest strategic market, policy tailwinds and launch execution ⁻ Affordability and access remain central to policy dialogue ⁻ Recent US commercialization: Yesafili (bAflibercept), Bosaya & Aukelso (bDenosumab), gLiraglutide ⁻ Regional supply network strengthened through local capabilities and strategic partnerships ▪ Europe: integrated portfolio in a well-established biosimilars and generics market ⁻ Combined portfolio of 11 biosimilars and eight generic medicines ⁻ Tailored retail and tender strategies ⁻ Evfraxy® (bDenosumab) and Abevmy® (bBevacizumab) launches across select markets ▪ Emerging Markets: access led growth through portfolio breadth and partnerships ⁻ Broader portfolio with expanded commercial capabilities ⁻ Local partnerships, CMOs and technology-transfer initiatives ⁻ Yesafili launch in Malaysia; continued bevacizumab leadership in Brazil
Page 5
Financial Highlights – Q1 FY27
Page 6
Financial Highlights – Q1 FY27 In ₹ Cr Q1 FY27 Q1 FY26 Q4 FY26 YoY% QoQ% Biopharmaceuticals - Biosimilars 2,855 2,458 2,756 16 4 - Generics 760 630* 776* 21 (2) Services 736 875 1,037 (16) (29) Revenue from Operations 4,336 3,942 4,517 10 (4) Total Revenue 4,391 4,022 4,569 9 (-4) R&D (Net) 240 205 277 17 (13) % of Revenue (Ex. Syngene) 7 7 8 EBITDA 902 846 1,073 7 (16) % Margin 21 21 23 Profit Before Tax (Before exceptional items) 141 114 328 24 (57) % Margin 3 3 7 Net Profit (Before exceptional items) 145 42 179 245 (19) Exceptional item, net of tax & NCI (4) (11) (53) Net Profit (Reported) 141 31 126 355 12 * Excluding cross charge of common utilities that was earlier included within Generics but is now appropriately included under “Unallocable expenditure/(income)”
Page 7
Biosimilars
Page 8
Biosimilars: Q1 FY27 Business Performance Update ▪ Financial Performance ⁻ Growth led primarily by North America market ⁻ EBITDA up 10% YoY , 25% EBITDA margin ⁻ R&D spend at 7% of revenue ▪ Growth momentum expected to build progressively through FY27, H2 to be meaningfully better ▪ Recent launches and market access progress provide visibility on a stronger second half ▪ EMA approval for second insulin drug product line in Malaysia doubles capacity and supports future growth In ₹ Cr Q1 FY27 Q1 FY26 Q4 FY26 YoY% QoQ% Segment Revenue 2,855 2,458 2,756 16 4 R & D 192 134 188 44 2 % of Revenue 7% 5% 7% EBITDA 728 662 720 10 1 % of Revenue 25% 27% 26%
Page 9
Generics
Page 10
Generics: Q1 FY27 Business Performance Update ▪ Financial Performance ⁻ Revenues up 21% YoY ⁻ EBITDA margin up by over 250bps QoQ ⁻ R&D spend at 6% of revenue ▪ Generic liraglutide was a key driver across multiple markets, including the USA ▪ Margin improvement driven by operating leverage and cost efficiency initiatives ▪ Peptides, fermentation and manufacturing investments provide a strong platform for utilization- led margin expansion In ₹ Cr Q1 FY27 Q1 FY26* Q4 FY26* YoY% QoQ% Segment Revenue 760 630 776 21 (2) R & D 47 70 89 (33) (47) % of Revenue 6% 11% 12% EBITDA 56 (35) 39 nm 44 % of Revenue 7% (6)% 5% * Excluding cross charge of common utilities that was earlier included within Generics but is now appropriately included under “Unallocable expenditure/(income)”
Page 11
Services
Page 12
In ₹ Cr Q1 FY27 Q1 FY26 Q4 FY26 YoY% QoQ% Segment Revenue 736 875 1,037 (16) (29) EBITDA 116 224 326 (48) (64) % of Revenue 15% 25% 31% Services: Q1 FY27 Business Performance Update ▪ Financial Performance ⁻ Performance impacted by lower offtake from a key biologics client and forex hedge losses ⁻ Partly offset by cost optimization initiatives ▪ Strengthening Capabilities ⁻ Strategic collaboration with BRIC-THSTI* enhances translational research and clinical development capabilities ⁻ Continued investment in Syn.AI@, digital technologies and emerging modalities ▪ Outlook ⁻ FY27 to be a transition year, with performance improving in 2H ⁻ New management team focused on sharpening commercial execution, strengthening delivery and building a more agile, cost-competitive organisation ⁻ Positioned for a return to sustainable growth from FY28 * Biotechnology Research & Innovation Council - Translational Health Science and Technology Institute; @Syngene’s AI-enabled scientific platform for accelerating drug discovery services
Page 13
Concluding Remarks
Page 14
Concluding Remarks: Q1 FY27 ▪ Growth Momentum Building ⁻ Recent launches and expanded manufacturing capacity support the next phase of growth ⁻ Performance expected to strengthen through FY27, led by Biosimilars ▪ Translating Scale into Returns ⁻ Focused on improving margins, free cash flow generation and RoCE ⁻ Generics profitability showing early benefits of operating leverage and fiscal prudence ▪ Positioned for Sustainable Value Creation ⁻ Integrated portfolio and global capabilities position us well for future opportunities ⁻ Committed to translating growth into stronger earnings and shareholder value
Page 15
Thank you Q&A